scholarly article | Q13442814 |
P2093 | author name string | D Moechars | |
F Van Leuven | |||
J Van Dorpe | |||
C Van den Haute | |||
K Spittaels | |||
I Tesseur | |||
P2860 | cites work | Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease | Q22248076 |
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein | Q22251280 | ||
Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease | Q24308731 | ||
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families | Q27860677 | ||
Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid | Q28279517 | ||
Selective alterations in the cellular distribution of apolipoprotein E immunoreactivity following transient cerebral ischaemia in the rat | Q28569838 | ||
Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth | Q28771743 | ||
Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females | Q33563135 | ||
Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line | Q33848287 | ||
Specific regional transcription of apolipoprotein E in human brain neurons | Q35745315 | ||
Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease | Q35754598 | ||
Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. | Q35846021 | ||
Expression of the Thy-1 glycoprotein gene by DNA-mediated gene transfer | Q36588769 | ||
Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. | Q36840098 | ||
Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia | Q56268222 | ||
Phosphorylation of tau protein is not affected in mice lacking apolipoprotein E | Q58216318 | ||
Regulation of Thy-1 gene expression in transgenic mice | Q69902613 | ||
Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions | Q70478363 | ||
Phosphorylation of tau in apolipoprotein E-deficient mice | Q70958117 | ||
A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele | Q71265364 | ||
A closely linked gene to apolipoprotein E may serve as an additional risk factor for Alzheimer's disease | Q71587380 | ||
Targeted inactivation of the mouse alpha 2-macroglobulin gene | Q71707001 | ||
ApoE genotype and survival from intracerebral haemorrhage | Q72020086 | ||
Neurite degeneration elicited by apolipoprotein E peptides | Q72408843 | ||
Effect of apolipoprotein E on neurite outgrowth and beta-amyloid-induced toxicity in developing rat primary hippocampal cultures | Q72996400 | ||
Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated | Q73507862 | ||
High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes | Q77319921 | ||
The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease | Q77340836 | ||
Synthesis of apolipoprotein E (ApoE) mRNA by human neuronal-type SK N SH-SY 5Y cells and its regulation by nerve growth factor and ApoE | Q77748850 | ||
Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs | Q37045150 | ||
Staging of Alzheimer's disease-related neurofibrillary changes | Q40416705 | ||
Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform | Q40806171 | ||
Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype | Q40817463 | ||
A test of the cytosolic apolipoprotein E hypothesis fails to detect the escape of apolipoprotein E from the endocytic pathway into the cytosol and shows that direct expression of apolipoprotein E in the cytosol is cytotoxic. | Q40965861 | ||
A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins | Q41056322 | ||
Evolution of the neuropathology of Alzheimer's disease. | Q41064104 | ||
Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene | Q41064715 | ||
Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein | Q41150323 | ||
The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization | Q41308477 | ||
Tau and ubiquitin immunoreactivity at different stages of formation of Alzheimer neurofibrillary tangles | Q41598172 | ||
Reactive astrocytes: cellular and molecular cues to biological function | Q41673434 | ||
PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model | Q41699855 | ||
Thy-1, the enigmatic extrovert on the neuronal surface | Q42111935 | ||
Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein | Q42795195 | ||
Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro | Q45081026 | ||
Age-related phosphorylation and fragmentation events influence the distribution profiles of distinct tau isoforms in mouse brain. | Q45946084 | ||
Indicator expression directed by regulatory sequences of the glial fibrillary acidic protein (GFAP) gene: in vivo comparison of distinct GFAP-lacZ transgenes | Q46156203 | ||
Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning | Q46163083 | ||
The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant | Q46323718 | ||
Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease | Q47700813 | ||
Regionally specific neuronal expression of human APOE gene in transgenic mice | Q47972600 | ||
A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. | Q48041239 | ||
Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls | Q48092219 | ||
Expression of Thy-1/lacZ fusion genes in the CNS of transgenic mice | Q48097010 | ||
GFAP promoter directs astrocyte-specific expression in transgenic mice | Q48163933 | ||
The -491A/T polymorphism of the Apolipoprotein E gene is associated with the ApoEepsilon4 allele and Alzheimer's disease | Q48230376 | ||
Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment | Q48307898 | ||
Intraneuronal ApoE in human visual cortical areas reflects the staging of Alzheimer disease pathology | Q48323914 | ||
The mouse Thy-1.2 glycoprotein gene: complete sequence and identification of an unusual promoter | Q48368454 | ||
Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. | Q48477194 | ||
Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes | Q48603343 | ||
Somatodendritic localization of phosphorylated tau in neonatal and adult rat cerebral cortex | Q48636064 | ||
Apolipoprotein E ∈4 Associated With Chronic Traumatic Brain Injury in Boxing | Q48659275 | ||
Cytoskeletal changes in the brains of mice lacking calcineurin A alpha | Q48754848 | ||
A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity | Q48864142 | ||
Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: implications for Alzheimer's disease | Q49082479 | ||
Neurodegenerative changes including altered tau phosphorylation and neurofilament immunoreactivity in mice transgenic for the serine/threonine kinase Mos. | Q49087978 | ||
Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease | Q49106878 | ||
Cystatin C and apolipoprotein E immunoreactivities in CA1 neurons in ischemic gerbil hippocampus | Q49114133 | ||
Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. | Q52041566 | ||
Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. | Q52050809 | ||
Expression of X-linked genes in androgenetic, gynogenetic, and normal mouse preimplantation embryos. | Q52211093 | ||
Apolipoprotein E ε4 allele is associated with deposition of amyloid β-protein following head injury | Q53200531 | ||
Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. | Q53204218 | ||
Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. | Q53206202 | ||
Induction of apolipoprotein E mRNA in the hippocampus of the gerbil after transient global ischemia. | Q53212645 | ||
ApoE synthesis in human neuroblastoma cells. | Q53220957 | ||
A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. | Q53221276 | ||
Cis-acting human ApoE tissue expression element is associated with human pattern of intraneuronal ApoE in transgenic mice. | Q53222443 | ||
Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. | Q53314304 | ||
Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele. | Q53315213 | ||
Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. | Q53327233 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 951-964 | |
P577 | publication date | 2000-03-01 | |
P1433 | published in | The American Journal of Pathology | Q4744259 |
P1476 | title | Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice | |
P478 | volume | 156 |
Q40398632 | A 13 kDa carboxy-terminal fragment of ApoE stabilizes Abeta hexamers |
Q36070145 | A novel Alzheimer disease locus located near the gene encoding tau protein. |
Q46080729 | A putative role for cell cycle-related proteins in microtubule-based neuroplasticity |
Q102075407 | APOE4 genetic polymorphism results in impaired recovery in a repeated mild traumatic brain injury model and treatment with Bryostatin-1 improves outcomes |
Q90246320 | APOEε4 potentiates the relationship between amyloid-β and tau pathologies |
Q43724620 | Activation of mitogen-activated protein kinase cascade and phosphorylation of cytoskeletal proteins after neurone-specific activation of p21ras. II. Cytoskeletal proteins and dendritic morphology |
Q30499574 | Alzheimer disease models and human neuropathology: similarities and differences |
Q89841160 | Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How |
Q36568983 | Alzheimer's disease: brain desmosterol levels. |
Q34024443 | Alzheimer's disease: neurodevelopment converges with neurodegeneration |
Q39611551 | Amyloid-β protein modulates the perivascular clearance of neuronal apolipoprotein E in mouse models of Alzheimer's disease |
Q48503462 | ApoE allelic variability influences pupil response to cholinergic challenge and cognitive impairment |
Q30539979 | ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice |
Q35823248 | ApoE4-specific Misfolded Intermediate Identified by Molecular Dynamics Simulations |
Q64068852 | ApoE4: an emerging therapeutic target for Alzheimer's disease |
Q36546467 | Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate neuropathology |
Q40658415 | Apolipoprotein E (apoE) uptake and distribution in mammalian cell lines is dependent upon source of apoE and can be monitored in living cells. |
Q37060457 | Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. |
Q39155261 | Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins |
Q37821616 | Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. |
Q24604376 | Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy |
Q40616184 | Apolipoprotein E and β‐amyloid (1–42) regulation of glycogen synthase kinase‐3β |
Q37117670 | Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons |
Q35794564 | Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer's disease. |
Q90732521 | Apolipoprotein E particle size is increased in Alzheimer's disease |
Q44591025 | Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease |
Q30497417 | Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice |
Q40571686 | Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer |
Q92583989 | Apolipoprotein E4: A Risk Factor for Successful Cognitive Aging |
Q22248091 | Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease |
Q34497951 | Apolipoprotein E: From lipid transport to neurobiology |
Q33337322 | Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. |
Q28265290 | Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease |
Q34621541 | Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases |
Q36963238 | Apolipoprotein e sets the stage: response to injury triggers neuropathology |
Q34688023 | Apolipoproteins and aging: emerging mechanisms |
Q50559366 | Association of White Matter Integrity and Cognitive Functions in Chinese Non-Demented Elderly with the APOE ɛ4 Allele. |
Q89791301 | Associations between brain inflammatory profiles and human neuropathology are altered based on apolipoprotein E ε4 genotype |
Q40621541 | Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease |
Q34995116 | Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease |
Q48639403 | Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice |
Q42008541 | Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology |
Q35978742 | Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice |
Q37536586 | Cognitive deficits and disruption of neurogenesis in a mouse model of apolipoprotein E4 domain interaction |
Q37352061 | Commonalities in the genetics of Alzheimer's disease and Parkinson's disease |
Q57972066 | Differential effects of apolipoprotein E isoforms on phosphorylation at specific sites on tau by glycogen synthase kinase-3β identified by nano-electrospray mass spectrometry |
Q34106518 | Experimental gerontology in Belgium: from model organisms to age-related pathologies |
Q35022620 | Expression of Tau40 induces activation of cultured rat microglial cells |
Q34053056 | Genetic connections between neurological disorders and cholesterol metabolism |
Q36753393 | Genetic influences on outcome following traumatic brain injury |
Q33811028 | Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology |
Q53237934 | Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. |
Q36961152 | Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease |
Q46804251 | High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. |
Q36115297 | Human apolipoprotein E4 targeted replacement in mice reveals increased susceptibility to sleep disruption and intermittent hypoxia |
Q45412375 | Human apolipoprotein E4 worsens acute axonal pathology but not amyloid-β immunoreactivity after traumatic brain injury in 3xTG-AD mice |
Q38657053 | Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer's disease pathogenesis |
Q44586222 | Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. |
Q40523596 | Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc |
Q28771380 | Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells |
Q35418351 | Introducing Human APOE into Aβ Transgenic Mouse Models |
Q28508278 | Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E |
Q40015743 | Intron-3 retention/splicing controls neuronal expression of apolipoprotein E in the CNS. |
Q48392448 | Investigation of Aβ phosphorylated at serine 8 (pAβ) in Alzheimer's disease, dementia with Lewy bodies and vascular dementia |
Q39909606 | Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease? |
Q37336139 | Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis |
Q34210006 | Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity |
Q37337930 | Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo |
Q34071519 | Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice |
Q47794190 | Molecular Mechanisms of the R61T Mutation in Apolipoprotein E4: A Dynamic Rescue |
Q33220562 | Morphological and morphometric alterations of Cajal-Retzius cells in early cases of Alzheimer's disease: a Golgi and electron microscope study |
Q37053940 | Motor impairment in Alzheimer's disease and transgenic Alzheimer's disease mouse models. |
Q51095457 | Mouse Models of Alzheimer's Disease. |
Q35540365 | Mouse models of Alzheimer's disease: The long and filamentous road |
Q34578769 | Mouse models of Alzheimer's disease: a quest for plaques and tangles |
Q44105472 | Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice. |
Q44795511 | Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. |
Q42675168 | Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. |
Q35070741 | Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice |
Q34976296 | Neuroplasticity in Alzheimer's disease |
Q34566571 | New developments in animal models of Alzheimer's disease |
Q34156138 | New insights into genetic and molecular mechanisms of brain degeneration in tauopathies |
Q53235325 | No evidence for cholinergic problems in apolipoprotein E knockout and apolipoprotein E4 transgenic mice. |
Q41351424 | Observation of the density and size of cells in hippocampus and vascular lesion in thalamus of GFAP-apoE transgenic mice |
Q48337243 | Phosphorylation state of tau in the hippocampus of apolipoprotein E4 and E3 knock-in mice |
Q36888445 | Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype |
Q46529938 | Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. |
Q35864607 | Progress toward identification of protease activity involved in proteolysis of apolipoprotein e in human brain |
Q35829610 | Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord |
Q35745836 | Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. |
Q24633831 | Relationships between expression of apolipoprotein E and beta-amyloid precursor protein are altered in proximity to Alzheimer beta-amyloid plaques: potential explanations from cell culture studies |
Q64114898 | Revisiting the Role of Insulin-Like Growth Factor-I Receptor Stimulating Activity and the Apolipoprotein E in Alzheimer's Disease |
Q46019370 | Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models. |
Q58028348 | Tau and transgenic animal models |
Q48390072 | Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease |
Q28211236 | Tau-associated neuropathology in ganglion cell tumours increases with patient age but appears unrelated to ApoE genotype |
Q38959290 | The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update |
Q38722713 | The Therapeutic Potential of Cell Identity Reprogramming for the Treatment of Aging-Related Neurodegenerative Disorders |
Q33841363 | The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease |
Q91743602 | The role of APOE4 in Alzheimer's disease: strategies for future therapeutic interventions |
Q28742884 | The ε3 and ε4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice |
Q47844521 | Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease |
Q35723358 | Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. |
Q48401292 | Transgenic mouse models for Alzheimer's disease: the role of GSK-3B in combined amyloid and tau-pathology |
Q58769184 | Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration |
Q52366535 | hnRNP R and its main interactor, the noncoding RNA 7SK, coregulate the axonal transcriptome of motoneurons. |